journal article·2019-09-09

Folic Acid-Conjugated Radioluminescent Calcium Tungstate Nanoparticles as Radio-Sensitizers for Cancer Radiotherapy

Vincenzo J. Pizzuti, Rahul Misra, Jaewon Lee, Sandra E. Torregrosa-Allen, Melanie P. Currie, Scott R. Clark, Anish P. Patel, Christopher R. Schorr, Yava Jones-Hall, Michael O. Childress, Jeannie M. Plantenga, Nicholas J. Rancilio, Bennett D. Elzey, You-Yeon Won

Publisher page

Abstract

Radiation therapy is a primary treatment modality for many forms of cancer. Normally, the highest tolerable dose of ionizing radiation is used to treat tumors, but limitations imposed by normal tissue complications present challenges for local tumor control. In light of this, a class of compounds called radio-sensitizers have been developed to enhance the effectiveness of radiation. Many of these are small molecule drugs found to interact favorably with radiation therapy, but recent advances have been made using nanoparticles as radio-sensitizers. Herein, we report the utilization of radio-luminescent calcium tungstate nanoparticles that emit photoelectrons, UV-A, and visible light during X-ray irradiation, acting as effective radio-sensitizers ("Radio Luminescence Therapy"). In addition, a folic acid-functionalized form of these nanoparticles was shown to enhance radio-sensitization in vitro and in murine models of head and neck cancer. Folic acid-functionalized particles were found to decrease UV-A-induced clonogenic cell survival relative to nonfunctionalized particles. Several possible mechanisms were explored, and the folic acid-functionalized particles were found to mediate this increase in efficacy likely by activating pro-proliferative signaling through folate's innate mitogenic activity, leading to decreased repair of UV-A-induced DNA lesions. Finally, a clinical case study of a canine sarcoma patient demonstrated the initial safety and feasibility of translating these folic acid-functionalized particles into the clinic as radio-sensitizers in the treatment of spontaneous tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Head and Neck Cancer Studies · Radiation Therapy and Dosimetry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Veterinary Clinical Sciences, Auburn University, 1010 Wire Road, Auburn, Alabama 36849, United States

Funding

Indiana Clinical and Translational Sciences Institute · Purdue Research Foundation · Purdue University Center for Cancer Research · National Institutes of Health · Purdue University · School of Chemical Engineering, Purdue University · Lodos Theranostics LLC

References (35)

Show source-provided references
1. 10.1186/1748-717X-6-5410.1186/1748-717X-6-54 ↗
2. 10.1016/j.semradonc.2011.12.00210.1016/j.semradonc.2011.12.002 ↗
3. 10.1200/JCO.2015.62.096310.1200/JCO.2015.62.0963 ↗
4. 10.1177/019459981453518310.1177/0194599814535183 ↗
5. 10.1093/annonc/mdi73510.1093/annonc/mdi735 ↗
6. 10.1038/nrc258710.1038/nrc2587 ↗
7. 10.1016/B978-1-4160-5897-7.00004-410.1016/B978-1-4160-5897-7.00004-4 ↗
8. 10.1053/srao.2003.5000210.1053/srao.2003.50002 ↗
9. Kwatra D. · Translational Cancer Research · 2013 · 2 · 330
10. 10.1021/acsnano.6b0140110.1021/acsnano.6b01401 ↗
11. 10.3390/ma603081710.3390/ma6030817 ↗
12. 10.2217/fon.12.9610.2217/fon.12.96 ↗
13. 10.1021/acsbiomaterials.8b0011910.1021/acsbiomaterials.8b00119 ↗
14. 10.1155/2016/737064210.1155/2016/7370642 ↗
15. 10.1016/j.canlet.2012.09.01210.1016/j.canlet.2012.09.012 ↗
16. 10.1016/j.addr.2004.02.00310.1016/j.addr.2004.02.003 ↗
17. 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F ↗
18. 10.1016/j.addr.2004.01.00110.1016/j.addr.2004.01.001 ↗
19. 10.1016/j.cellsig.2015.03.02010.1016/j.cellsig.2015.03.020 ↗
20. 10.18632/oncotarget.965110.18632/oncotarget.9651 ↗
21. 10.1016/j.radonc.2012.08.00610.1016/j.radonc.2012.08.006 ↗
22. 10.1200/JCO.1998.16.4.131810.1200/JCO.1998.16.4.1318 ↗
23. 10.1021/acsami.6b0072710.1021/acsami.6b00727 ↗
24. 10.1021/acs.macromol.6b0062110.1021/acs.macromol.6b00621 ↗
25. 10.1039/c0jm04410e10.1039/c0jm04410e ↗
26. 10.1111/j.1365-2818.2006.01706.x10.1111/j.1365-2818.2006.01706.x ↗
27. 10.1007/s10103-017-2317-410.1007/s10103-017-2317-4 ↗
28. 10.1002/hed.2100310.1002/hed.21003 ↗
29. 10.2147/IJN.S4632710.2147/IJN.S46327 ↗
30. 10.1093/nar/gks82410.1093/nar/gks824 ↗
31. 10.1074/jbc.M11159820010.1074/jbc.M111598200 ↗
32. 10.4161/cc.9.2.1047510.4161/cc.9.2.10475 ↗
33. 10.1016/j.jconrel.2019.04.03310.1016/j.jconrel.2019.04.033 ↗
34. 10.1111/j.1476-5810.2006.00097.x10.1111/j.1476-5810.2006.00097.x ↗
35. 10.1021/acs.bioconjchem.6b0045110.1021/acs.bioconjchem.6b00451 ↗